OvaScience (Boston, MA) a development-stage biotechnology company focused on mitochondria rejuvenation to improve fertility, closed a Series A financing. Participants include Bessemer Venture Partners and Longwood Founders Fund.

Allena Pharmaceuticals (Newton, MA) a preclinical-stage biopharmaceutical company focused on nephrologic and urologic conditions, closed a $15M Series A financing. Participants include Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures.

Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $15M Series D financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital, CVF and Bessemer Venture Partners.

Verastem (Boston, MA) a development stage biopharmaceutical company focused on the treatment of cancer by targeting stem cells, closed a $32M Series B financing. Participants include Advanced Technology Ventures, Astellas Venture Management, Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital. Thanx for your patience as we catch-up.

Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $24M million Series C financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners.

Verastem (Boston, MA) a development-stage biopharmaceutical company focused on stem cell oncology therapeutics, closed a $16M Series A financing. Participants include Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital.

Alnara Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on liprotamase, a pancreatic enzyme replacement therapy, for the treatment of pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, pancreatectomy and other pancreatic conditions, closed a $35M Series B financing. Participants include MPM Capital, Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners.

On-Q-lty (Waltham, MA) a development stage molecular diagnostics company incorporating microfluidics and biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors, closed a $5M Series A financing, bringing the total round to $26M. Participants include Atlas Venture, Mohr Davidow Ventures, Bessemer Venture Partners, Physic Ventures and Northgate Capital. Note: [...]

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust. Note: 2009 Year-in-Review Trend Analysis [...]